[1] Desai AP, Knapp SM, Orman ES, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis-a US population-based study. J Hepatol, 2020, 73:1092-1099.
[2] Francoz C. Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb. J Hepatol, 2020, 72:1043-1045.
[3] 尹伟, 李成忠. 肝硬化急性肾损伤发病风险和治疗应答影响因素的前瞻性研究. 肝脏,2020,25:791-796.
[4] Treeprasertsuk S, Wongkarnjana A, Jaruvongvanich V, et al. Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions. BMC Gastroenterol,2015,15:140.
[5] Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology, 2008,48:2064-2077.
[6] Puthumana J, Ariza X, Belcher JM, et al. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol,2017,15:1003-1013.
[7] Huelin P, Solà E, Elia C, et al. Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. Hepatology, 2019,70:319-333.
[8] Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care,2007,11:R31.
[9] Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract,2012,120:c179-c184.
[10] Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut,2015,64:531-537.
[11] Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology, 2014,60:622-632.
[12] Fagundes C, Pépin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol, 2012, 57:267-273.
[13] Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J,2008,84:662-670.
[14] 庞国菊, 武玉晶, 刘爽, 等. 肝硬化继发急性肾损伤患者血清胱抑素C和中性粒细胞明胶酶相关脂质运载蛋白的水平及其诊断价值. 中华肝脏病杂志,2019:65-67.
[15] 尹伟, 李成忠. 基于NGAL的模型在肝硬化急性肾损伤早期诊断和鉴别诊断中的意义. 肝脏,2021,26:247-251.
[16] Jaques DA, Spahr L, Berra G, et al. Biomarkers for acute kidney injury in decompensated cirrhosis: A prospective study. Nephrology (Carlton),2019,24:170-180
[17] 康晓征, 赵勇, 乐磊, 等. 肝型脂肪酸结合蛋白对比白介素18对肝硬化失代偿期急性肾损伤患者的诊断价值. 安徽医科大学学报,2018,53:1289-1293.
[18] Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail,2016,38:1567-1573.
[19] Moresco RN, Bochi GV, Stein CS, De Carvalho JAM, Cembranel BM, Bollick YS. Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta,2018,487:15-21.
[20] Shao X, Tian L, Xu W, et al. Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One,2014,9:e84131.
[21] 姚梁, 张培珠, 钟金成. 血液及尿液中CysC、KIM-1、NGAL水平在肝硬化继发急性肾功能损伤患者中的诊断价值. 中国急救复苏与灾害医学杂志,2021,16:68-71.
[22] Yap DY, Seto WK, Fung J, et al. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. Dig Liver Dis,2017,49:202-206.
[23] 杨俊伟, 张靖华, 韩健乐. L-FABP联合IL-18检测在肝硬化失代偿期急性肾损伤中的诊断价值. 中国校医,2020,34:445-446.
[24] 袁剑峰, 张翠芳, 苏振宏. 胰岛素样生长因子结合蛋白7在肝硬化患者急性肾损伤时的诊断价值. 皖南医学院学报, 2018,37:233-236.
[25] 韩焕钦, 欧进军, 冯冰, 等. 尿IGFBP7及TIMP-2在失代偿期乙型肝炎肝硬化急性肾损伤中的应用价值. 中华肝脏病杂志,2020,28:760-765.
[26] 李明, 陈入溧, 吴振平, 等. 尿液中IGFBP7和TIMP-2联合检测对HBV相关慢加急性肝衰竭致急性肾损伤的预测价值. 临床肝胆病杂志,2019,35:1560-1564.
[27] Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ,2020, 370:m2687.
[28] Allegretti AS, Ortiz G, Wenger J, et al. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol, 2015, 2015:108139.
[29] Xiong J, Pu L, Xiong H, et al. Evaluation of the criteria of hepatorenal syndrome type of acute kidney injury in patients with cirrhosis admitted to ICU. Scand J Gastroenterol,2018,53:1590-1596.
[30] Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open,2020,3:e2019209.
[31] Bell M, Larsson A, Venge P, et al.. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Dis Markers,2015, 2015:158658.
[32] Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep, 2018, 8:7962. |
